CHIR-99021 (CT99021) HCl

Catalog No.S2924

Molecular Weight(MW): 501.8

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.

Cited by 126 Publications

Cell Stem Cell, 2019, 24(5):802-811

PubMed: 30880024 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):462-477

PubMed: 28111200 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):518-532

PubMed: 28017796 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Nat Biotechnol, 2014, 32(11):1121-33

PubMed: 25211370 ( click the link to review the publication )

Nature, 2013, 500(7461):222-6

PubMed: 23812591 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(9):1152-1163

PubMed: 31481791 ( click the link to review the publication )

Blood, 2019, blood.2019001037

PubMed: 31570489 ( click the link to review the publication )

Nat Commun, 2019, 10(1):928

PubMed: 30804331 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2939

PubMed: 31270324 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3477

PubMed: 31375664 ( click the link to review the publication )

Sci Adv, 2019, 5(11):eaax7525

PubMed: 31807705 ( click the link to review the publication )

Dev Cell, 2019, 50(2):212-228.e6

PubMed: 31178404 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Cell Rep, 2019, 26(13):3643-3656

PubMed: 30917318 ( click the link to review the publication )

Cell Rep, 2019, 29(8):2461-2472

PubMed: 31747613 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Oncogene, 2019, 38(15):2788-2799

PubMed: 30542117 ( click the link to review the publication )
Mol Metab, 2019, 24:80-97

PubMed: 30930126 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0605

PubMed: 31395667 ( click the link to review the publication )

Front Neurosci, 2019, 13:867

PubMed: 31551670 ( click the link to review the publication )

Front Physiol, 2019, 10:818

PubMed: 31316396 ( click the link to review the publication )

Cell Cycle, 2019, 18(19):2495-2508

PubMed: 31411525 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):5440-5452

PubMed: 31059099 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5230

PubMed: 30531796 ( click the link to review the publication )

Sci Adv, 2018, 4(5):eaat0351

PubMed: 29795786 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Cell Rep, 2018, 25(7):1966-1981.e4

PubMed: 30428361 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2563-2576

PubMed: 30485820 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Stem Cell Reports, 2018, 11(2):497-513

PubMed: 30033084 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):22

PubMed: 29426364 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):598

PubMed: 29789524 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(9):1095-1106

PubMed: 30251630 ( click the link to review the publication )

Dig Dis Sci, 2018, 63(10):2604-2616

PubMed: 29948558 ( click the link to review the publication )

Biol Open, 2018, 7(9)

PubMed: 30135081 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Curr Protoc Hum Genet, 2018, 10.1002/cphg.64

PubMed: 29979824 ( click the link to review the publication )

Methods Mol Biol, 2018, 1733:127-136

PubMed: 29435928 ( click the link to review the publication )
Cell Res, 2017, 27(6):815-829

PubMed: 28429771 ( click the link to review the publication )

Mol Cell, 2017, 66(4):568-576

PubMed: 28483418 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(31):25929-25940

PubMed: 28718622 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3107

PubMed: 29022923 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )

Stem Cell Res Ther, 2017, 8(1):156

PubMed: 28676082 ( click the link to review the publication )

Sci Rep, 2017, 7(1):9490

PubMed: 28842634 ( click the link to review the publication )

Biofabrication, 2017, 9(2):025007

PubMed: 28287080 ( click the link to review the publication )

JCI Insight, 2017, 2(18)

PubMed: 28931764 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Sci Rep, 2016, 6:23817

PubMed: 27026509 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )

Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )
Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )

Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )

Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )
Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )

Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )
Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )

Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	M1nqb2Z2dmO2aX;uJGF{e2G7	MYezJO69VQ>?	NHO5XG01KGh?	NIO4SYtFVVOR	MUPJcohq[mm2czDwdoVi\Gmyb3P5eIUh\GmoZnXy[Y51cWG2aX;u	NEXVdHMyOjB3NUKwNC=>
insulin receptor–expressing CHO-IR	M2XtOGZ2dmO2aX;uJGF{e2G7	NVH4c29qPTByIH7N	MUezNEBucW5?	MnnsSG1UVw>?	MX\BZ5RqfmG2ZYOgS4x6[2:pZX6gV5lvfGijc3WgLGdUMQ>?	MmHNNVI3ODZ2OUe=
H4IIE	NHH1dY5HfW6ldHnvckBCe3OjeR?=	MmTZNVAh\|ryP	MljINlQhcA>?	MXXEUXNQ	MXTS[Yd2dGG2ZYOg{tIu[2G2ZX7pckBi[3Srdnn0fUBidmRiVFnSSUBkd262YXnubY5oKHC{b33veIVzKGGldHn2bZR6	Mn\mNVU{PTBzOUW=
Oct4/Sox2/Klf4-infected MEFs	MV3GeY5kfGmxbjDBd5NigQ>?	NECybXkyOCEQvF2=	MnS4Nlgh\A>?	M1nuOGROW09?	MY\Qdo9ud3SnczDNSWZ{KHKncILv[5JidW2rbnegWJJidnOmdXPl[EBjgSCRY4S0MEBUd3h{LDDhcoQhU2yoNB?=	M{jXXFE6QDN7MEW1
Sca-1+ HPC	M{nJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuyJO69VQ>?	M4DWc\|Yh\A>?	Ml\qSG1UVw>?	M2e3WXN6dmW{Z3nzeIlk[WyueTDwdo9ud3SnczDTZ4EuOSwEoFjQR{Bxem:uaX\ldoF1cW:wIHHu[EBkd2yxbomg[o9zdWG2aX;uJJRw\2W2aHXyJJdqfGhiRVfG	NH\ve4ozOTZ{NEO0PC=>
HMC1.2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nIbVMxKM7:TR?=	NHTmfGs4OiCq	NHjIcJdFVVOR	MVPS[YR2[2W\|IHPlcIwhe3W{dnn2ZYw>	NUDV[2xROjJyM{mzNFE>
Endothelial cell(EC)	NWT6OnpKTnWwY4Tpc44hSXO\|YYm=	MlX3N{DPxE1?		MUXEUXNQ	NWLaclc1WHKxbX;0[ZMh\W6mb4To[Yxq[WxiY3XscEApTUNrIHTp[oZmemWwdHnheIlwdg>?	M3[4UlIzODV{MEC2
PANC1	NYfPRldSSXCxcITvd4l{KEG\|c3H5	NUHlbnViyqB3IN88US=>	NYDYdXdZPzJiaB?=	NVrDXGY1TE2VTx?=	NIf3WoxVemmpZ3Xyd{BidiCjcH;weI91cWNicnXzdI9ve2V?	M3HSWFIzOjBzMUi2
INS-1E	M17RU2Z2dmO2aX;uJGF{e2G7	NIrCN2kzNjVizszN	MXSyOEBp	M4TGN2ROW09?	MnrnTY5lfWOnczDhJJJm\HWldHnvckBw\iCQUEGgc5ZmemW6cILld5Nqd25?	MnXENlI1Ojd5MES=
hiPSC-NPs	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTjOoc{6oDLzszN	NH\od4s4OiCq	MlmwSG1UVw>?	MljpTY5kemWjc3XzJINmdGxicILvcIln\XKjdHnvcuKh	NXjxRllqOjJ4NEK2PFc>
platelets	MVLGeY5kfGmxbjDBd5NigQ>?	NHPnZmUyOCEQvF2=	MUmxOUBucW5?	Ml[5SG1UVw>?	NFnxR5VKdmO{ZXHz[ZMhfGi{b33ibY4udWWmaXH0[YQheGyjdHXs[ZQh[WepcnXnZZRqd25iYX7kJGFVWCC\|ZXPy[ZRqd25?	MU[yN\|I{QTh5Nx?=
DN3	MVrGeY5kfGmxbjDBd5NigQ>?	MYSxNEDPxE1?	M2nNPFk3KGh?	M{Lw[WROW09?	MWnJcoNz\WG\|ZYOgZ4VtdCCmZY\lcI9xdWWwdDDhcoQheHKxbHnm[ZJifGmxbh?=	NGCwOVczOzV{Nkm4PS=>
embryonic stem cells (ESC)	NXjNeYJZTnWwY4Tpc44hSXO\|YYm=	NFn4XZM{KML3TR?=	NX3meW9jOTFiZB?=	NUf4RZQ4TE2VTx?=	Ml7aVJJwdW:2ZYOgd4Vt\i2{ZX7le4FtKG:oIH7hx893\S22eYDlJI1wfXOnIHXtZpJ6d26rYzDzeIVuKGOnbHzzJEhGW0Nr	NFLyPIwzOzh2M{OxNi=>
H460	M2e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLWUHg2KML3TR?=	MkTINlQhcA>?	NHjTSWxFVVOR	MWrQdo9ud3SnczDj[YxtKHC{b3zp[oVz[XSrb36=	NWL0PY82OjR\|Nke2PFg>
H157	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT0OUDDvU1?	NG\UZY0zPCCq	NVT5c\|ZsTE2VTx?=	NEPEdWNRem:vb4Tld{Bk\WyuIIDyc4xq\mW{YYTpc44>	NIW0RWUzPDN4N{[4PC=>
H460	NX;LWHZZSXCxcITvd4l{KEG\|c3H5	M2G5PFUhyrWP	NUTYUJNHOjRiaB?=	Mn[zSG1UVw>?	NVK4ToNPSXS2ZX71ZZRmeyClZXzsJIFxd3C2b4Ppdy=>	M3LZc\|I1OzZ5Nki4
H157	MYDBdI9xfG:\|aYOgRZN{[Xl?	M1jENlUhyrWP	M1fsUFI1KGh?	MmPzSG1UVw>?	M4fSW2Rw\XNibn;0JJNq\26rZnnjZY51dHliYX\m[YN1KGGyb4D0c5Nqew>?	MXGyOFM3PzZ6OB?=
A549	NHzLR49CeG:ydH;zbZMhSXO\|YYm=	NXnxcYlsPSEEtV2=	NV\rW2F[OjRiaB?=	MY\EUXNQ	NFu1XWhKdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYO=	M1H3VVI1OzZ5Nki4
Neural progenitor cells	M37DTmZ2dmO2aX;uJGF{e2G7	M{PEZ\|Mh\|ryP	NWGzbJBCOTBiZB?=	M{TPZmROW09?	NXvjSZpDUW6mdXPld{Bo\W6ncnH0bY9vKG:oIH7leZJidCCycn;n[Y5qfG:{IHPlcIx{	NVq3Z\|g5OjR4M{iwN\|Q>
ES-D3	NHXVdWNEgXSxdH;4bYMhSXO\|YYm=	NUWxfGF7OTEEoN88US=>	NGDEW2o{KGR?	M{LZOWROW09?	Mn;tTY5lfWOnczDtc4RmemG2ZTDjfZRwfG:6aXPpeJkhf2m2aDDJR\|UxKG:oIESuPUDPxE1?	M{jyOVI1Pzd7M{[1
ES-CCE	MVLDfZRwfG:6aXOgRZN{[Xl?	M{W3N\|ExyqEQvF2=	M4TCZVMh\A>?	M2jMXGROW09?	Mk\rTY5lfWOnczDtc4RmemG2ZTDjfZRwfG:6aXPpeJk>	NIPCPWszPDd5OUO2OS=>
ES-D3	M2HLZmZ2dmO2aX;uJGF{e2G7	M17CRlXDqM7:TR?=	MUizJIQ>	NV3UUWk{TE2VTx?=	NFn4dGlUfHKxbnfsfUBqdmS3Y3XzJJRp\SCjY4Tpeol1gSCxZjDXcpQw[mW2YT3jZZRmdmmwIIDheIh4[Xl?	MWWyOFc4QTN4NR?=
ES-CCE	MlPzSpVv[3Srb36gRZN{[Xl?	NHfDeJo2yqEQvF2=	MlzaN{Bl	NID4U5pFVVOR	M4XqNnN1em:wZ3z5JIlv\HWlZYOgeIhmKGGldHn2bZR6KG:oIGfueE9j\XSjLXPheIVvcW5icHH0bJdigQ>?	MUCyOFc4QTN4NR?=
SW982	NIXP[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwMkG0NVYh\|ryP	MWLTRW5ITVJ?
GCT	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3r6N2lEPTB;MD6zNFY4OiEQvF2=	MVnTRW5ITVJ?
769-P	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HRNmlEPTB;MD61PFQ6QSEQvF2=	MX\TRW5ITVJ?
LOXIMVI	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUC0[4RKUUN3ME2wMlU5QDN{IN88US=>	MX7TRW5ITVJ?
D-336MG	M1rkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPrUGRxUUN3ME2wMlg1PjJizszN	NYraclFKW0GQR1XS
S-117	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PnUGlEPTB;MD65NlE{OSEQvF2=	MmXFV2FPT0WU
D-247MG	NHjWSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPsdmYxUUN3ME2wMlk1QDV{IN88US=>	MlLxV2FPT0WU
TYK-nu	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[zN2lEPTB;MT6wO\|kyOiEQvF2=	MlXPV2FPT0WU
A498	M3W5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFwM{C0Olkh\|ryP	MXHTRW5ITVJ?
BCPAP	NYTlO\|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[4TWM2OD1zLk[2PFk5KM7:TR?=	M4nCVHNCVkeHUh?=
KYSE-180	NYTIfIY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTFwN{K3PFgh\|ryP	M3LkOHNCVkeHUh?=
MIA-PaCa-2	NFmycZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz0TWM2OD1zLke1PVc4KM7:TR?=	MkG0V2FPT0WU
HCC1395	M3qyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\UXmFCUUN3ME2xMlc5Ojd\|IN88US=>	NIXibHpUSU6JRWK=
RS4-11	NITndItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVeyOmlyUUN3ME2xMlk2PDF3IN88US=>	MV\TRW5ITVJ?
NCI-H2122	NULxb5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXtTWM2OD1{LkK3Olg1KM7:TR?=	M{W1[HNCVkeHUh?=
SNU-423	NG\EcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkCyTWM2OD1{LkS5O\|g4KM7:TR?=	MULTRW5ITVJ?
SK-LMS-1	M4j4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLaeYY6UUN3ME2yMlY1OTJ6IN88US=>	NFrlNnVUSU6JRWK=
RPMI-7951	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zHWGlEPTB;Mj63NFE6OyEQvF2=	NFH4PZZUSU6JRWK=
COLO-829	M4jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXDRmFTUUN3ME2yMlc3PTRizszN	NV\5VI8xW0GQR1XS
SCC-9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTJwOUW0PFUh\|ryP	MVnTRW5ITVJ?
A704	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nm[2lEPTB;Mz6wPFEzKM7:TR?=	M2XsZXNCVkeHUh?=
HOP-62	NFzKdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTNwM{[wOVQh\|ryP	NWTlcoVZW0GQR1XS
HCC1569	NXroUpA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHYeGdKSzVyPUOuOFg{ODVizszN	MYPTRW5ITVJ?
A172	NHjrdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTNwN{W0PVgh\|ryP	NVTM[Gd{W0GQR1XS
MOLT-16	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHjTWM2OD1\|Lki4OVU3KM7:TR?=	M3jkU3NCVkeHUh?=
TE-15	NHnVSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfzTWM2OD1\|Lkm1N\|Q{KM7:TR?=	MoHvV2FPT0WU
OE19	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HtfmlEPTB;Mz65OlQ2OSEQvF2=	NWKwOVFsW0GQR1XS
MHH-ES-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHQN5JkUUN3ME20MlA1PTR3IN88US=>	MWHTRW5ITVJ?
NKM-1	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkH5TWM2OD12LkGzPVcyKM7:TR?=	MY\TRW5ITVJ?
RCC10RGB	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfwTWM2OD12LkK5OFc6KM7:TR?=	NWDMVYxxW0GQR1XS
BxPC-3	NIPYTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\oTWM2OD12LkewN\|kyKM7:TR?=	M2PubHNCVkeHUh?=
ALL-PO	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXnT5VKUUN3ME20Mlg{QDV6IN88US=>	NXLzToRiW0GQR1XS
SK-OV-3	NUSwW4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkiyTWM2OD12Lkm5N\|Qh\|ryP	MWjTRW5ITVJ?
SW1710	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXe1ZlI2UUN3ME21MlQzPDV4IN88US=>	NIXQNGhUSU6JRWK=
NCI-H2452	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluyTWM2OD13LkS1OlI5KM7:TR?=	NU\1c\|ZmW0GQR1XS
D-392MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkT1TWM2OD13LkS5NVQ2KM7:TR?=	NGjKUXRUSU6JRWK=
LB2518-MEL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTVwN{K2Nlch\|ryP	NVLCZ3h{W0GQR1XS
BL-41	NG\ncpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[4TWM2OD13LkixNlY3KM7:TR?=	Mni5V2FPT0WU
WM-115	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLZTWM2OD13LkixOVA6KM7:TR?=	M3TGPHNCVkeHUh?=
SK-MEL-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;rTWM2OD14LkO4N\|Q1KM7:TR?=	NHzLToJUSU6JRWK=
CGTH-W-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUS5N\|JtUUN3ME22MlQyPyEQvF2=	NEXkPXpUSU6JRWK=
BB65-RCC	M1HyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLhS5V5UUN3ME22MlU{OTl3IN88US=>	MXvTRW5ITVJ?
CAL-85-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjaTWM2OD14Lk[wPVM3KM7:TR?=	NUGwcmlPW0GQR1XS
RT-112	NY\yPZo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnwVnpKUUN3ME23MlE3PDV4IN88US=>	M1rxW3NCVkeHUh?=
MC116	NX21e5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvj[XZmUUN3ME23MlI5PjlzIN88US=>	NHv5ZnZUSU6JRWK=
G-361	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TFcmlEPTB;Nz60OlU3OSEQvF2=	NVjwXmhSW0GQR1XS
SW1417	NUThNW83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PyS2lEPTB;Nz62OFU5PCEQvF2=	MX;TRW5ITVJ?
MV-4-11	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRThwNUSzNFQh\|ryP	M3vIeXNCVkeHUh?=
CAL-72	NImxWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHoTWM2OD16Lke2NVE{KM7:TR?=	MXvTRW5ITVJ?
MKN28	NXu4cWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\Wd4NKSzVyPUiuPFg2OTZizszN	NVLiVlJtW0GQR1XS
MEG-01	NVTMZnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRThwOUmwOFMh\|ryP	M1XLb3NCVkeHUh?=
ACHN	NV;mS\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLlTWM2OD17LkOwOVQ3KM7:TR?=	M4fzWXNCVkeHUh?=
NCI-H1755	NGnw[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\3U\|VsUUN3ME25MlM6QTh4IN88US=>	NWTReJBvW0GQR1XS
NCI-H64	NVjwXpdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTlwNEKyOVUh\|ryP	MkXoV2FPT0WU
COLO-205	NWLQOo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HkRWlEPTB;OT60N\|gzOSEQvF2=	M3;uNXNCVkeHUh?=
CTV-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrLb2ZKSzVyPUmuOFM5QTRizszN	NIWy[ZRUSU6JRWK=
U-2-OS	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL1VmF2UUN3ME25MlQ2ODB4IN88US=>	MYjTRW5ITVJ?
LB996-RCC	NIfBZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LoSGlEPTB;OT61NlM6PyEQvF2=	MVHTRW5ITVJ?
SK-N-DZ	NFj3VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\3dWlEPTB;OT62OVc1OiEQvF2=	M1\PbXNCVkeHUh?=
EFM-19	NFro[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XjdWlEPTB;OT63OVU3PiEQvF2=	NED1SolUSU6JRWK=
DBTRG-05MG	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTlwN{e3O{DPxE1?	M1ftNXNCVkeHUh?=
U-118-MG	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjkOXBKSzVyPUmuPVQ1PDRizszN	NXjsNVdJW0GQR1XS
LB1047-RCC	NIXzSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITsPHhKSzVyPUmuPVk4QThizszN	MkDOV2FPT0WU
NCI-H28	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLwXJFKSzVyPUGwMlQ1OTNizszN	MmLHV2FPT0WU
MZ2-MEL	NHzGdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\oXGlEPTB;MUCuOFY4PyEQvF2=	NWjGUYRUW0GQR1XS
M059J	NHfSNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFyLk[xNFIh\|ryP	NUe1UZpvW0GQR1XS
HT-3	M2e5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PUe2lEPTB;MUCuOlE4QSEQvF2=	NIDOXWlUSU6JRWK=
SNU-387	M3rqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFyLkeyN\|Uh\|ryP	MVvTRW5ITVJ?
NCI-H526	M375WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGqyT3hKSzVyPUGxMlE{PjVizszN	Mme0V2FPT0WU
HEL	NFPPRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPTTWM2OD1zMT62OVc6KM7:TR?=	MlnhV2FPT0WU
PA-1	NGDM[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DwbmlEPTB;MUGuPVMh\|ryP	MofDV2FPT0WU
PC-14	MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3PTWM2OD1zMj6zNlQh\|ryP	MmjZV2FPT0WU
C8166	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYG4fWhTUUN3ME2xN{4zOzF6IN88US=>	NHGxNZpUSU6JRWK=
NCI-H82	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3VdYNmUUN3ME2xN{4zQTB7IN88US=>	NIPCW4dUSU6JRWK=
DSH1	NG\ZUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7KSI1uUUN3ME2xN{4{QDd7IN88US=>	NUXvUHFEW0GQR1XS
T98G	NWDHeotWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF\|LkS3NVch\|ryP	MUjTRW5ITVJ?
KU812	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHReHh7UUN3ME2xN{42OTd3IN88US=>	M4LIXXNCVkeHUh?=
SW48	NHnQOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1npeWlEPTB;MUOuO\|I3PSEQvF2=	M4H3TnNCVkeHUh?=
MEL-HO	Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTF\|Lki4Nlkh\|ryP	M1voN3NCVkeHUh?=
SF539	NYjrdlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTF2LkCxNVYh\|ryP	NXzwOVZFW0GQR1XS
NB1	NUPBSW5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mme0TWM2OD1zND6xPVM2KM7:TR?=	NHjXdlZUSU6JRWK=
ST486	NULhT5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXYeI5WUUN3ME2xOE4zOjVzIN88US=>	M2TNOHNCVkeHUh?=
LoVo	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mme0TWM2OD1zNT6yOlU6KM7:TR?=	M{jubHNCVkeHUh?=
NH-12	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUP5OHVtUUN3ME2xOk4xODl5IN88US=>	MYfTRW5ITVJ?
CCRF-CEM	M3T2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3icIhKSzVyPUG2MlY4ODJizszN	M2TyNXNCVkeHUh?=
Daudi	NI\o[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rkcmlEPTB;MUeuOlE1QSEQvF2=	MU\TRW5ITVJ?
SIMA	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTLdmhKSzVyPUG3MlkyOThizszN	MYXTRW5ITVJ?
8305C	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3uy[2lEPTB;MUiuOVMxPSEQvF2=	NHHOW3FUSU6JRWK=
EM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoL5TWM2OD1zOD62NlQ5KM7:TR?=	NYfCZ\|FkW0GQR1XS
SNU-449	NHvkTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\u[GFIUUN3ME2xPE44OTVizszN	MUjTRW5ITVJ?
A101D	M4LSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfBcXdKSzVyPUG5MlI1OyEQvF2=	MUDTRW5ITVJ?
MHH-NB-11	NFvnc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nGcWlEPTB;MUmuOVM1OiEQvF2=	M2PNUnNCVkeHUh?=
Becker	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrYb3FKSzVyPUKwMlE4PzdizszN	M3uyUnNCVkeHUh?=
NCI-H727	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvhTWM2OD1{MD6yNVY6KM7:TR?=	NGi4W3lUSU6JRWK=
HCC1187	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3GwRmlEPTB;MkCuN\|U5QSEQvF2=	M2rURnNCVkeHUh?=
KYSE-450	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTJzLkWzOVQh\|ryP	MnW3V2FPT0WU
SK-MEL-28	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XU[GlEPTB;MkGuOlg3OyEQvF2=	MmfEV2FPT0WU
BPH-1	M2nHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPHTWM2OD1{MT63NFM2KM7:TR?=	MoLDV2FPT0WU
EoL-1-	NWrHNlhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJzLkizPFUh\|ryP	M{PZeXNCVkeHUh?=
TGBC24TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYL3eINIUUN3ME2yNU45QTV5IN88US=>	NUfmcmV2W0GQR1XS
KARPAS-299	NXLRRWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPpVHVnUUN3ME2yNk4yQTV2IN88US=>	NUjENo1LW0GQR1XS
SW684	M2[5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJ{LkK4OVgh\|ryP	NIfYeIpUSU6JRWK=
RXF393	M3;HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTJ{Lk[wOlgh\|ryP	NUXzZ2tkW0GQR1XS
LS-513	NESwPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJ{Lk[xPVIh\|ryP	NVvtNlJTW0GQR1XS
KURAMOCHI	NIP4e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDzfWw{UUN3ME2yNk44ODZ7IN88US=>	NULkNJd1W0GQR1XS
GI-1	MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnrSWR4UUN3ME2yNk44QDRzIN88US=>	MVrTRW5ITVJ?
M14	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjne2Q3UUN3ME2yN{4yOTN{IN88US=>	NX7LTWFmW0GQR1XS
REH	NF6weW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rWN2lEPTB;MkOuNVY6QSEQvF2=	NXzVVnREW0GQR1XS
K5	NXzmOZB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlWwTWM2OD1{Mz61OFg3KM7:TR?=	NIDqN\|lUSU6JRWK=
PANC-10-05	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTrTWM2OD1{ND6wPFk5KM7:TR?=	M4W3OHNCVkeHUh?=
HMV-II	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13KN2lEPTB;MkSuNlE3OyEQvF2=	NX:xXIhzW0GQR1XS
NCI-H1963	M1TVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DQOGlEPTB;MkSuNlg{QSEQvF2=	NWi4XW5GW0GQR1XS
LU-139	NF3RXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfOTWM2OD1{ND64N\|Uh\|ryP	MlLpV2FPT0WU
KASUMI-1	NXjtXpFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPMbYhKSzVyPUK0Mlk{OjhizszN	M1[2dHNCVkeHUh?=
RO82-W-1	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfVTWM2OD1{Nj63N\|c4KM7:TR?=	MmniV2FPT0WU
NCI-H1770	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTWTWM2OD1{Nj64PVg3KM7:TR?=	Mm\6V2FPT0WU
SNG-M	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzFTWM2OD1{Nz6yNlcyKM7:TR?=	M36xZ3NCVkeHUh?=
KLE	NUW3NYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{W3fGlEPTB;MkeuNlU3PSEQvF2=	M1PoR3NCVkeHUh?=
NCI-H2170	NGXmOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXETWM2OD1{Nz61NlgzKM7:TR?=	MVLTRW5ITVJ?
COLO-792	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;ZbVBKSzVyPUK3Mlc4OjhizszN	MXfTRW5ITVJ?
ES8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknZTWM2OD1{Nz63PFE1KM7:TR?=	MWPTRW5ITVJ?
MC-CAR	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:wTWM2OD1{Nz63PVA4KM7:TR?=	M1PBd3NCVkeHUh?=
SU-DHL-1	M1LwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTJ5Lkm0O\|Qh\|ryP	MofCV2FPT0WU
OAW-28	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHuXmx4UUN3ME2yPE4xODV{IN88US=>	Mn3rV2FPT0WU
C32	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny0TWM2OD1{OD6wPFI3KM7:TR?=	MnrZV2FPT0WU
SW872	NIHLWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJ6LkWzNlYh\|ryP	Mmj3V2FPT0WU
JiyoyeP-2003	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvyTWM2OD1{OT62O\|E6KM7:TR?=	NIniVI9USU6JRWK=
A204	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJ7Lk[4Nlgh\|ryP	NGTQRmhUSU6JRWK=
IST-MES1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nPPWlEPTB;MkmuO\|A6OiEQvF2=	MmPPV2FPT0WU
LCLC-103H	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3m1emlEPTB;M{CuNlA2QSEQvF2=	M4[5VnNCVkeHUh?=
CAKI-1	M2m3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH0ZpZpUUN3ME2zNE4zPjV4IN88US=>	NEjSUJhUSU6JRWK=
NALM-6	M3\zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr1cHJKSzVyPUOwMlQ6PjVizszN	NXHDW203W0GQR1XS
SK-MM-2	NXn1c2JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjzPJJSUUN3ME2zNE46Pzl{IN88US=>	NF\BWGJUSU6JRWK=
LB373-MEL-D	M{WySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLjTWM2OD1\|MT6wNFQ4KM7:TR?=	MlHvV2FPT0WU
CAS-1	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPETWM2OD1\|MT63OlY2KM7:TR?=	NFK1[FZUSU6JRWK=
KNS-42	NEnhWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlWwTWM2OD1\|MT64OlYzKM7:TR?=	NY\HOHhqW0GQR1XS
SW948	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPMXZpKSzVyPUOyMlc2PDhizszN	NVv3SHdEW0GQR1XS
HCC1143	M1Pwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXe3W5hwUUN3ME2zNk44QTd7IN88US=>	NV60NWxsW0GQR1XS
NCI-H1648	MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzVU4hbUUN3ME2zNk45PDZ5IN88US=>	MXTTRW5ITVJ?
RVH-421	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rzbWlEPTB;M{OuNVY5KM7:TR?=	MoTnV2FPT0WU
KU-19-19	M4PBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjMNoNqUUN3ME2zN{44PTN2IN88US=>	NW\vWmEzW0GQR1XS
PFSK-1	M3vjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknaTWM2OD1\|ND65NlQyKM7:TR?=	M3XQZXNCVkeHUh?=
TK10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LsSGlEPTB;M{WuNVMzOiEQvF2=	M1LienNCVkeHUh?=
IGROV-1	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYq3fGNOUUN3ME2zOU4{PDF4IN88US=>	M17SNXNCVkeHUh?=
EFE-184	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfOWldzUUN3ME2zOU46OTdizszN	NVjhXZY2W0GQR1XS
8505C	NXLYTXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPtN3JMUUN3ME2zOU46Ojl2IN88US=>	M2f4c3NCVkeHUh?=
SK-UT-1	NFfmUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTN4LkOzN\|Eh\|ryP	NILrb4ZUSU6JRWK=
MKN1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTlSIVFUUN3ME2zOk45PDR2IN88US=>	NYTGSm9uW0GQR1XS
no-10	M2HlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P4VWlEPTB;M{iuNVI6PCEQvF2=	NIjlRVlUSU6JRWK=
HT-144	NH73cZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN6LkK1O\|Uh\|ryP	NIriSpVUSU6JRWK=
CMK	M3nrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTN6LkSxOlIh\|ryP	MmP4V2FPT0WU
KM12	NIDrfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S0[GlEPTB;M{iuOVk6QCEQvF2=	MV;TRW5ITVJ?
HCC2218	M3fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvWUZJKSzVyPUSwMlU5PDlizszN	MUPTRW5ITVJ?
BE-13	NGPBbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTRzLkS0O\|Mh\|ryP	MVnTRW5ITVJ?
SK-CO-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LZdGlEPTB;NEGuO\|c2PSEQvF2=	M1r6SXNCVkeHUh?=
MPP-89	M1yxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLmV5lKSzVyPUSxMlkzOTFizszN	NUnNXZVLW0GQR1XS
NY	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3iTWM2OD12Mj6xPFAyKM7:TR?=	M{HWZXNCVkeHUh?=
IST-MEL1	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDITWM2OD12Mj62PVM5KM7:TR?=	M1PSRXNCVkeHUh?=
HCT-116	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3WyVWlEPTB;NEOuNlA6QSEQvF2=	MXjTRW5ITVJ?
LB831-BLC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTR\|Lk[5O{DPxE1?	M1vteHNCVkeHUh?=
TE-8	NYTpcot3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTsTWM2OD12Mz63PFk2KM7:TR?=	MWnTRW5ITVJ?
SR	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fMXGlEPTB;NEOuPFY4OyEQvF2=	M4LOb3NCVkeHUh?=
ESS-1	MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3m5fWlEPTB;NESuNlA3OiEQvF2=	MnjzV2FPT0WU
KYSE-270	M1:2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLON\|hKSzVyPUS1MlA1OzdizszN	NWDic3NKW0GQR1XS
H4	NVXoTnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn1TWM2OD12NT6zNlk3KM7:TR?=	NXzOWog4W0GQR1XS
COLO-800	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\Hb2hKSzVyPUS1MlU5QThizszN	NIDEdm5USU6JRWK=
Ramos-2G6-4C10	NF\WRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PKOmlEPTB;NE[uNFc2PSEQvF2=	Mof2V2FPT0WU
no-11	M3PEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTR4LkKwN\|Eh\|ryP	NWHtPYo1W0GQR1XS
UACC-62	M2r3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLLSmJKSzVyPUS2Mlg3ODhizszN	MX3TRW5ITVJ?
D-542MG	M2jtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnlTItWUUN3ME20O{41PTh7IN88US=>	NFHwOmdUSU6JRWK=
NCI-H747	NVTnbnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXWT2RKUUN3ME20O{44OjZ2IN88US=>	M1fBZXNCVkeHUh?=
HCC2998	NWfXU5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL5WZRKSzVyPUS4MlI6QDJizszN	NWXyTWNrW0GQR1XS
SNB75	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnVZoFHUUN3ME20PE41OTF6IN88US=>	M{LhcnNCVkeHUh?=
COR-L105	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfk[oJKSzVyPUS4Mlk4OyEQvF2=	NHL4RmxUSU6JRWK=
SNU-C1	NXvCV3VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrWN\|RSUUN3ME20PU4{OjB5IN88US=>	M3TD[nNCVkeHUh?=
LC4-1	M1jl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1H1eWlEPTB;NEmuPFkyOiEQvF2=	M3nORXNCVkeHUh?=
KS-1	NXXPVoF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTVyLkKyNlUh\|ryP	MmTzV2FPT0WU
NCI-H1793	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDXTWM2OD13MT6yN\|Eh\|ryP	NGfCSm9USU6JRWK=
NCI-H1650	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTVzLkW4OFkh\|ryP	MXfTRW5ITVJ?
MCF7	NUGyeVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHRTWM2OD13MT63OVU1KM7:TR?=	NHzHPW9USU6JRWK=
SK-N-AS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPyfmdpUUN3ME21NU45OjhzIN88US=>	M4i1[3NCVkeHUh?=
SW837	NWjUU4M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjLUFJQUUN3ME21NU46Pzh3IN88US=>	M37oZnNCVkeHUh?=
DB	M{nXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTVzLkm4OVUh\|ryP	MWPTRW5ITVJ?
CESS	NXjMblJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTV{LkG0OUDPxE1?	MXjTRW5ITVJ?
CHP-126	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljQTWM2OD13Mz61NVY6KM7:TR?=	NITUTYVUSU6JRWK=
COLO-824	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTV\|Lk[5O\|Yh\|ryP	MnPNV2FPT0WU
MG-63	NXSxfodxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTV\|LkmzPFEh\|ryP	M3z2VnNCVkeHUh?=
KGN	NIHYW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTV\|Lkm1PUDPxE1?	M2W3NHNCVkeHUh?=
697	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTV2LkG1OVUh\|ryP	NVTqZ3l4W0GQR1XS
MC-IXC	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS4Zld4UUN3ME21OE41OzZ2IN88US=>	MVfTRW5ITVJ?
A375	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTV2LkiwOVkh\|ryP	Ml33V2FPT0WU
LXF-289	NIK2WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjQNopKSzVyPUW1MlUxPjZizszN	MnHWV2FPT0WU
ES6	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzmTWM2OD13NT64PFk6KM7:TR?=	NXW1dVQ{W0GQR1XS
DV-90	NILjPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDiO\|Z3UUN3ME21OU45QTF5IN88US=>	M{PNUnNCVkeHUh?=
RCM-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnflTWM2OD13Nj6wNFc5KM7:TR?=	NIC5S4hUSU6JRWK=
NCI-H2405	NWixc3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHwSGlKSzVyPUW2MlE3QTNizszN	NWHhOoZTW0GQR1XS
DoTc2-4510	M1Tqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPMU\|FXUUN3ME21Ok43ODV5IN88US=>	NILaS\|dUSU6JRWK=
RPMI-8866	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTV5LkK0NVIh\|ryP	M{X4O3NCVkeHUh?=
BV-173	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnuVFRKSzVyPUW3MlUyPDJizszN	NWO5[XhPW0GQR1XS
LCLC-97TM1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{exdmlEPTB;NUmuNFU2OyEQvF2=	M3HmPXNCVkeHUh?=
HT-1376	NFnBRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzkc3BKSzVyPUW5MlA6OjFizszN	MUTTRW5ITVJ?
ACN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTV7LkG1PFch\|ryP	NXLhZos2W0GQR1XS
LU-134-A	NGLwVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF31U2NKSzVyPUW5MlYxOTZizszN	NF7zbmhUSU6JRWK=
SiHa	M1PrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPRT\|lKSzVyPUW5MlY1QDdizszN	NFfLZZpUSU6JRWK=
EKVX	NXHoVY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTZzLkS5OVgh\|ryP	NXW5e3N1W0GQR1XS
NMC-G1	Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;OR5dKSzVyPU[xMlkzPDJizszN	Ml7ZV2FPT0WU
NCI-H1734	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD5TWM2OD14MT65OlY{KM7:TR?=	M3fGPHNCVkeHUh?=
K-562	NIPYcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjKSXVKSzVyPU[yMlI1PTJizszN	MlzqV2FPT0WU
T-24	NV;2eJRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LI[WlEPTB;NkKuO\|EzPiEQvF2=	MVHTRW5ITVJ?
SCH	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzsVJdmUUN3ME22OE4zOzVzIN88US=>	M1HBTXNCVkeHUh?=
AN3-CA	M1\zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvvOIJbUUN3ME22OE4{ODN3IN88US=>	M2rYU3NCVkeHUh?=
MFE-296	NU\5NHZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvWNHppUUN3ME22OE41PDd\|IN88US=>	NH\QVXFUSU6JRWK=
HuCCT1	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1P5WWlEPTB;NkeuNFM4PCEQvF2=	NXn5OpQ3W0GQR1XS
NCI-H1703	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTZ6LkGxO\|Eh\|ryP	Mk\oV2FPT0WU
C-4-II	NXHnVWk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\lTWM2OD14OT6zOlA4KM7:TR?=	NUmyfo43W0GQR1XS
NCI-H2342	NYnMSnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFGxRVZKSzVyPU[5MlM6PjFizszN	NHnCT5BUSU6JRWK=
Hs-578-T	M{PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC1TWM2OD15MD6zJO69VQ>?	NW\MZ\|Z5W0GQR1XS
HCC1806	NWXmVpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIexfoZKSzVyPUexMlQ2QDdizszN	NIPzWY9USU6JRWK=
EW-16	M1zCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTdzLke0NVUh\|ryP	M{TPb3NCVkeHUh?=
KALS-1	NGrObpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu3WYNKSzVyPUezMlU1PzVizszN	NFnhS3pUSU6JRWK=
RT4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTd\|LkW3OFIh\|ryP	MofGV2FPT0WU
LS-411N	NGS0SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTd2LkK1Nlgh\|ryP	MkLnV2FPT0WU
SK-MEL-1	NUfxbopRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH5TWM2OD15NT64NFE6KM7:TR?=	MmjHV2FPT0WU
8-MG-BA	M1y4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX6TWM2OD15Nj6xNFk3KM7:TR?=	NIDkbXZUSU6JRWK=
HSC-3	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\IRVc4UUN3ME23O{4xOjh{IN88US=>	NYHWXlk3W0GQR1XS
NB6	NUPLZVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\XVIhmUUN3ME23PE4yOjl7IN88US=>	MVjTRW5ITVJ?
PANC-03-27	NXi1dW86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlK0TWM2OD15OD60N\|Uh\|ryP	NEnoS\|hUSU6JRWK=
KP-N-YS	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LnOmlEPTB;N{iuOVg4QCEQvF2=	MX\TRW5ITVJ?
SF295	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHre4dKSzVyPUe5Mlk2PTNizszN	NFy1fGtUSU6JRWK=
HCE-T	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TXcWlEPTB;OECuNVU5QCEQvF2=	Ml\PV2FPT0WU
KYSE-410	NWjmPYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRThyLkK4OVch\|ryP	MV3TRW5ITVJ?
NB12	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37kPWlEPTB;OECuPVM3QSEQvF2=	NX:ycoh1W0GQR1XS
NCI-H661	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRThzLkO0OEDPxE1?	M3HEVXNCVkeHUh?=
NCI-H1417	NUmyXW4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4C2dWlEPTB;OEGuOFM3QCEQvF2=	NVnlT\|IzW0GQR1XS
KMOE-2	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRThzLki1N\|Eh\|ryP	MkfCV2FPT0WU
SW1573	M3j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTh{LkW4PVMh\|ryP	NXnGU5ZUW0GQR1XS
BFTC-905	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHK1No1KSzVyPUi0MlAyPzJizszN	Ml:4V2FPT0WU
SBC-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLDc2lPUUN3ME24OE4xOjB6IN88US=>	MYPTRW5ITVJ?
MDA-MB-175-VII	NYS4dXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLTTWM2OD16NT63OFI3KM7:TR?=	NWnUeXdyW0GQR1XS
TE-12	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUT1Tm51UUN3ME24PU4{PzRzIN88US=>	MmnCV2FPT0WU
NCI-H650	NF7WN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTh7Lki3NlQh\|ryP	Ml7EV2FPT0WU
C-33-A	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTlyLkW0JO69VQ>?	NXnLPYxSW0GQR1XS
MZ7-mel	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fk[2lEPTB;OUGuNlY4PiEQvF2=	MWPTRW5ITVJ?
BOKU	NH;LUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkm5TWM2OD17Mj62PVU4KM7:TR?=	NVPSfoJvW0GQR1XS
CAL-33	NH3tWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzkTWM2OD17Mz6wOlAyKM7:TR?=	MYDTRW5ITVJ?
23132-87	NFfISopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrmeHZZUUN3ME25N{4yPjhizszN	M{OyV3NCVkeHUh?=
J82	M33a[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfFTWM2OD17Mz63PFEyKM7:TR?=	MX3TRW5ITVJ?
MZ1-PC	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjBZlBUUUN3ME25OE42QTh2IN88US=>	MWrTRW5ITVJ?
MEL-JUSO	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmP3TWM2OD17ND65OVQh\|ryP	NIXlT2hUSU6JRWK=
RMG-I	NIPOSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWj4NIxFUUN3ME25OU4yODd{IN88US=>	M2KwcnNCVkeHUh?=
A2058	NHfQcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrhTWM2OD17NT60OlE4KM7:TR?=	M33QXHNCVkeHUh?=
Caov-4	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ntO2lEPTB;OUWuOlg2KM7:TR?=	MYXTRW5ITVJ?
OS-RC-2	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7GTWM2OD17Nz60OlEh\|ryP	M2S4[XNCVkeHUh?=
MKN7	NEnqfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTl5Lke0N\|kh\|ryP	NILLfpNUSU6JRWK=
U-698-M	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fvNmlEPTB;OUiuPVQ5QSEQvF2=	MWrTRW5ITVJ?
PC-3	NEDsPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTl7LkC1OlQh\|ryP	NFr1Z3hUSU6JRWK=
NCI-H292	M3fPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\VTWM2OD17OT6zNFA1KM7:TR?=	NFTtfIpUSU6JRWK=
IGR-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTl7LkOxNVkh\|ryP	M3HxOHNCVkeHUh?=
Mewo	NVTtPGxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDBRYxKSzVyPUm5MlU3ODNizszN	M3ntenNCVkeHUh?=
LU-65	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFyMT6wPFEh\|ryP	MWrTRW5ITVJ?
Saos-2	M37QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W2fGlEPTB;MUCxMlQ{PyEQvF2=	MXrTRW5ITVJ?
TE-11	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPtTWM2OD1zMEGuO\|I1KM7:TR?=	M1nsW3NCVkeHUh?=
SK-MES-1	M3Lve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFyMT63OlIh\|ryP	MVHTRW5ITVJ?
KE-37	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfSWI5KSzVyPUGwNk46PSEQvF2=	NYHIdmwzW0GQR1XS
MKN45	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LPcmlEPTB;MUCzMlU5PCEQvF2=	MoPzV2FPT0WU
UM-UC-3	M{n6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\FTopKSzVyPUGwN{45PDJizszN	MWrTRW5ITVJ?
SNU-C2B	NGDjTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTFyNT6wNlMh\|ryP	NWHGepZ3W0GQR1XS
RPMI-8226	M{jTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKwUpJKSzVyPUGwOk43PzhizszN	M1rEPXNCVkeHUh?=
PANC-08-13	NEDyb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL4c3V4UUN3ME2xNFYvQDVizszN	M1XybnNCVkeHUh?=
NCI-H23	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFyOD6zOVch\|ryP	MV3TRW5ITVJ?
HOP-92	M17mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7xSlJxUUN3ME2xNFgvPDd3IN88US=>	M1X2U3NCVkeHUh?=
FTC-133	NYC1NlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFyOD60PFgh\|ryP	NHjE[3JUSU6JRWK=
D-263MG	NXm5bmdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HFU2lEPTB;MUC4Mlk3OSEQvF2=	Ml;2V2FPT0WU
DU-145	NEXYXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULUZXBuUUN3ME2xNFkvQTR3IN88US=>	M3PqVnNCVkeHUh?=
A253	M1i1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLTR4dKSzVyPUGxNE41PzlizszN	NVPLT\|ZCW0GQR1XS
HCT-15	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjYbY9KUUN3ME2xNVAvPjZzIN88US=>	MofkV2FPT0WU
WSU-NHL	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXmTWM2OD1zMUKuNFEh\|ryP	NITzc2lUSU6JRWK=
U031	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Kxc2lEPTB;MUGyMlA3PSEQvF2=	MY\TRW5ITVJ?
MDA-MB-157	NFXEOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jZ[2lEPTB;MUGyMlQ6KM7:TR?=	MlrTV2FPT0WU
NEC8	M1zIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFzMj62NlQh\|ryP	NIPVUohUSU6JRWK=
SIG-M5	M2ruWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLJTWM2OD1zMUOuNVI2KM7:TR?=	NFzsUZJUSU6JRWK=
786-0	M4nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFzMz60OVMh\|ryP	NWDZVGhEW0GQR1XS
DMS-273	NVrLRmZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPScopYUUN3ME2xNVUvPjF5IN88US=>	NIjCVHZUSU6JRWK=
Calu-6	M121e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfPWnpKSzVyPUGxOk44QThizszN	M2jR[HNCVkeHUh?=
HCC1599	NGLiV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrIXG97UUN3ME2xNVcvOTV4IN88US=>	M2nSfXNCVkeHUh?=
OVCAR-8	NGXlV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLtdYdsUUN3ME2xNVcvPjZ6IN88US=>	M4Gxc3NCVkeHUh?=
ATN-1	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XH[GlEPTB;MUG3MlgzQCEQvF2=	NYKzSHV7W0GQR1XS
RKO	M{frTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFzNz64PVgh\|ryP	NIjFZ3ZUSU6JRWK=
SKG-IIIa	NGP4dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFzOD6xNVYh\|ryP	NHPlW3JUSU6JRWK=
SUP-T1	NF;ROY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTYTWM2OD1zMUiuPVU3KM7:TR?=	MkTmV2FPT0WU
KNS-81-FD	NU[5SpNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHqTWM2OD1zMUmuOFE4KM7:TR?=	NXfRN3hjW0GQR1XS
OVCAR-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4KzWGlEPTB;MUG5MlkyPSEQvF2=	MorDV2FPT0WU
NCI-N87	NXPwS41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXxV3I{UUN3ME2xNlEvODR2IN88US=>	NXz0N2NGW0GQR1XS
HuP-T4	NHjhUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17UNmlEPTB;MUKxMlU2KM7:TR?=	MlXBV2FPT0WU
KYSE-140	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;OTWM2OD1zMkKuNVQyKM7:TR?=	NH7DO3lUSU6JRWK=
HAL-01	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXTfGZRUUN3ME2xNlIvPDl7IN88US=>	NGLvWFhUSU6JRWK=
HT-29	M1zpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofqTWM2OD1zMkKuO\|c5KM7:TR?=	MW\TRW5ITVJ?
OPM-2	M1HrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX2TWM2OD1zMkOuNVc3KM7:TR?=	MWTTRW5ITVJ?
SW1463	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF{ND6wO\|ch\|ryP	M1HDXnNCVkeHUh?=
NCI-H2087	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;i[2lEPTB;MUK0MlI5OyEQvF2=	M3jNTXNCVkeHUh?=
UMC-11	NUfRZnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDCTWM2OD1zMk[uNFM5KM7:TR?=	MlrrV2FPT0WU
EB-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvYXmE{UUN3ME2xNlcvODF\|IN88US=>	Mlv5V2FPT0WU
HEC-1	M{LhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTF{OT6xPVgh\|ryP	NVmxOZllW0GQR1XS
LU-99A	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Di[GlEPTB;MUK5Mlk{OSEQvF2=	MWLTRW5ITVJ?
VMRC-RCZ	NXXHeIcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF\|MD6zO\|Uh\|ryP	NVLvUphmW0GQR1XS
MFH-ino	NGDLfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF\|MT6xNVQh\|ryP	Ml3HV2FPT0WU
HT-1080	M4n6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rNTGlEPTB;MUOyMlIxPCEQvF2=	MnnkV2FPT0WU
CTB-1	NFKzcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnXe\|c2UUN3ME2xN\|IvQDl5IN88US=>	NGTiW2pUSU6JRWK=
Capan-2	NFX2fpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVexTWN[UUN3ME2xN\|MvQTd3IN88US=>	MlTuV2FPT0WU
BB30-HNC	NF\2bpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHp[WNOUUN3ME2xN\|QvOTF4IN88US=>	NYnjWWtZW0GQR1XS
CP50-MEL-B	M4O0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHRTWM2OD1zM{SuNkDPxE1?	NVHUR5ZXW0GQR1XS
JEG-3	NVzVZpZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrGbYlKSzVyPUGzOE4{PTlizszN	MnHwV2FPT0WU
NCI-H1437	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LCOWlEPTB;MUO0MlU6KM7:TR?=	NUe3ZZZ7W0GQR1XS
NOS-1	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7xUWVJUUN3ME2xN\|QvPzZ3IN88US=>	M2rxNXNCVkeHUh?=
G-402	NHXvNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDuOoY2UUN3ME2xN\|UvOjl3IN88US=>	NWHMeZg1W0GQR1XS
OAW-42	NHzzXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofJTWM2OD1zM{euPFU3KM7:TR?=	NVnRUHQyW0GQR1XS
Ca-Ski	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF\|OD64N\|Eh\|ryP	NV20NXNkW0GQR1XS
BHT-101	NXfGNZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rGd2lEPTB;MUSwMlIxQCEQvF2=	MmDhV2FPT0WU
OVCAR-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTF2MD63OFkh\|ryP	MVzTRW5ITVJ?
Detroit562	NUPZVIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF2MT60OlYh\|ryP	MmPLV2FPT0WU
OCI-AML2	M4\Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7nWYJKSzVyPUG0NU42ODdizszN	MXjTRW5ITVJ?
OE33	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTGU3JZUUN3ME2xOFEvPzl6IN88US=>	MVrTRW5ITVJ?
YKG-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XaV2lEPTB;MUSyMlg5QSEQvF2=	MluyV2FPT0WU
CCF-STTG1	M2T1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTF2Mz6zN\|Qh\|ryP	M4GyV3NCVkeHUh?=
NCI-H810	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nJZ2lEPTB;MUSzMlY5PyEQvF2=	MVHTRW5ITVJ?
SCC-25	NWTx[VdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[5WWlEPTB;MUS0MlAxPSEQvF2=	NV;iZXM1W0GQR1XS
HTC-C3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrMZ29KSzVyPUG0OU4xPzVizszN	M1HWZnNCVkeHUh?=
G-401	NES4SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XF[GlEPTB;MUS1Mlg{PSEQvF2=	NGDVdYZUSU6JRWK=
OMC-1	M4\LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF2NT65Olch\|ryP	NGf3VGZUSU6JRWK=
LK-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTF2Nz6xOFMh\|ryP	Ml3PV2FPT0WU
SW13	NGfPXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmmwTWM2OD1zNEeuNlU{KM7:TR?=	M1LwR3NCVkeHUh?=
BB49-HNC	NYW1NYVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknVTWM2OD1zNEeuOFA1KM7:TR?=	M{DZRnNCVkeHUh?=
DMS-114	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTCcJRuUUN3ME2xOFcvPDRzIN88US=>	M{DhNXNCVkeHUh?=
GCIY	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;teWlEPTB;MUS3Mlc6PyEQvF2=	NIT3TVdUSU6JRWK=
GAMG	M1;uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTF2OD6yOFch\|ryP	MXfTRW5ITVJ?
KYSE-520	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoK2TWM2OD1zNEiuOVQh\|ryP	MlzvV2FPT0WU
LB647-SCLC	NUO1WphjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF2OD61OlIh\|ryP	NEjsVINUSU6JRWK=
639-V	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrlPGFKSzVyPUG0PE44ODVizszN	Ml36V2FPT0WU
TE-9	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;HOIVzUUN3ME2xOFkvPDR\|IN88US=>	NGrPfodUSU6JRWK=
Caov-3	NUnFdVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLiTWM2OD1zNEmuO\|E1KM7:TR?=	MkjBV2FPT0WU
L-540	NXXvT4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVruSXJtUUN3ME2xOFkvPzVizszN	MmP0V2FPT0WU
NCI-H748	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljxTWM2OD1zNUCuNlA6KM7:TR?=	Mn\HV2FPT0WU
GDM-1	NXT3NYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlr3TWM2OD1zNUGuNVM2KM7:TR?=	NETqe29USU6JRWK=
GAK	NYfqXlJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvJTWM2OD1zNUGuN\|c1KM7:TR?=	NYL4dJNmW0GQR1XS
AsPC-1	M1TpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF3Mj63OlQh\|ryP	NV3iN2NXW0GQR1XS
MDA-MB-361	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPkPVBKSzVyPUG1N{4yPjRizszN	MX3TRW5ITVJ?
TT	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTF3Mz60PUDPxE1?	NIfWWJZUSU6JRWK=
Calu-1	M4fBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPNZnd{UUN3ME2xOVQvODB\|IN88US=>	NHK4SFBUSU6JRWK=
RERF-LC-MS	NEe3UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHQTWM2OD1zNUSuO\|czKM7:TR?=	NGXuZ2ZUSU6JRWK=
DK-MG	NGXLTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DNdWlEPTB;MUW1MlE5OyEQvF2=	Mm\wV2FPT0WU
CAL-120	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXYTWM2OD1zNUWuPFIyKM7:TR?=	NGDuTWRUSU6JRWK=
HCC1419	NHvy[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXnZ2F[UUN3ME2xOVYvODd5IN88US=>	NVy5RYdbW0GQR1XS
DG-75	NYnKSIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTF3Nj62PVQh\|ryP	NGDCNopUSU6JRWK=
HCC38	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XvdGlEPTB;MUW3MlM3QSEQvF2=	NUi4V3VNW0GQR1XS
HCC70	NGX2S3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHGOVVKSzVyPUG1PU4zPDJizszN	NXjPXGZHW0GQR1XS
ES4	NETzU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2n3fGlEPTB;MUW5MlM6PiEQvF2=	NEjz[3VUSU6JRWK=
NCI-H2052	NFHye\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjLZmhjUUN3ME2xOVkvPTh\|IN88US=>	MlnzV2FPT0WU
EFO-27	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX2SmZSUUN3ME2xOlAvPTh2IN88US=>	NXzSVmI1W0GQR1XS
CAL-62	NGTZ[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnITWM2OD1zNkKuOlE{KM7:TR?=	NXzGcXRuW0GQR1XS
CHP-212	NHPMdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2joXGlEPTB;MU[zMlYzPiEQvF2=	NITVdmFUSU6JRWK=
AU565	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\RWXpKSzVyPUG2N{43PCEQvF2=	M17qPXNCVkeHUh?=
Ca9-22	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfTZW5KSzVyPUG2OE4{OjFizszN	NUfzfYtzW0GQR1XS
EFO-21	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T3eWlEPTB;MU[1MlQ2KM7:TR?=	M1zEWnNCVkeHUh?=
KINGS-1	NEHjWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUn3WY1zUUN3ME2xOlcvOzV2IN88US=>	NV3VWYpqW0GQR1XS
JVM-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nUOGlEPTB;MU[3MlQ2OSEQvF2=	NH[2U2hUSU6JRWK=
OVCAR-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXyTWM2OD1zNkiuN\|A6KM7:TR?=	MXLTRW5ITVJ?
Calu-3	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDSdGZKSzVyPUG2PE4{OTFizszN	MljYV2FPT0WU
CP66-MEL	NXjqcWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4D1R2lEPTB;MU[4MlQyPSEQvF2=	MonlV2FPT0WU
KYSE-150	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTF4OT62N\|Yh\|ryP	Mle2V2FPT0WU
Daoy	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfhTIJFUUN3ME2xOlkvQDlzIN88US=>	NIrBUYdUSU6JRWK=
HUTU-80	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjZTJNKSzVyPUG3NU4xOzJizszN	MV\TRW5ITVJ?
SW620	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTF5MT61N\|Uh\|ryP	MYDTRW5ITVJ?
HuO-3N1	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPLTWM2OD1zN{KuNlc{KM7:TR?=	M2LtU3NCVkeHUh?=
HH	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzZ[5dKSzVyPUG3N{45PDhizszN	MX7TRW5ITVJ?
ME-180	M3noVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFK5d5FKSzVyPUG3OE4xOTZizszN	Ml\OV2FPT0WU
SW756	M4DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF5ND64OlMh\|ryP	M2O3XHNCVkeHUh?=
LNCaP-Clone-FGC	NVexcodWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXDUpZ4UUN3ME2xO\|UvQDZzIN88US=>	M1vGb3NCVkeHUh?=
YT	NUX1eYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfFdnZKSzVyPUG3Ok4{QTlizszN	NE\4SmtUSU6JRWK=
EW-3	NIPkepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3W1XGlEPTB;MUe2MlU2PSEQvF2=	MVnTRW5ITVJ?
COLO-741	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37GdmlEPTB;MUe3MlU3OSEQvF2=	M4n4bnNCVkeHUh?=
SK-NEP-1	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvHOHc1UUN3ME2xO\|cvQDB4IN88US=>	MlvxV2FPT0WU
NB10	M1T0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLSTWM2OD1zN{euPFQ3KM7:TR?=	Mn;nV2FPT0WU
SF126	NUTjV4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLrTWM2OD1zN{muOFMzKM7:TR?=	MYfTRW5ITVJ?
NCI-H522	NWW1TGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2iz[WlEPTB;MUixMlA2QSEQvF2=	MUDTRW5ITVJ?
PSN1	M163XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTF6MT62OkDPxE1?	NXjBSIVFW0GQR1XS
GI-ME-N	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnKTWM2OD1zOEGuOlczKM7:TR?=	NI\4coNUSU6JRWK=
SBC-5	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTDflVKSzVyPUG4NU46OzRizszN	M1zwXXNCVkeHUh?=
ONS-76	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILQ[pZKSzVyPUG4Nk4{QDdizszN	MoPmV2FPT0WU
LOUCY	NILOTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXaTWM2OD1zOEKuOlg5KM7:TR?=	NFq5SndUSU6JRWK=
SN12C	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIe2fpNKSzVyPUG4Nk45OjlizszN	MYLTRW5ITVJ?
A427	NEPUNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXQTWM2OD1zOESuOlMyKM7:TR?=	NX3EO45UW0GQR1XS
DOK	NXzHN3V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[4eZRKSzVyPUG4OE43PDNizszN	MoHPV2FPT0WU
MDA-MB-415	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TBW2lEPTB;MUi0MlY2OSEQvF2=	NUKzTIZyW0GQR1XS
MRK-nu-1	NIfoNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXtZZNzUUN3ME2xPFQvQTd{IN88US=>	MYTTRW5ITVJ?
LB2241-RCC	NHHx[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PBZWlEPTB;MUi1MlE1PSEQvF2=	MmDjV2FPT0WU
NCI-H1563	M3XQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXEN\|JKSzVyPUG4OU4zODlizszN	NVrMdoxTW0GQR1XS
MDA-MB-453	NILDZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPabZV{UUN3ME2xPFYvQTRzIN88US=>	NGrmW2ZUSU6JRWK=
MONO-MAC-6	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTF6Nz6zPVIh\|ryP	MmXEV2FPT0WU
CAPAN-1	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;lTWlEPTB;MUi3MlQ2OyEQvF2=	NUjjdIZyW0GQR1XS
SK-LU-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV65dlZiUUN3ME2xPFgvPDJ6IN88US=>	MlXjV2FPT0WU
NCI-H1299	Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfSUnpKSzVyPUG4PE44OTlizszN	Ml\lV2FPT0WU
KG-1	NHvzO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF6OT63PVgh\|ryP	NGDWdG9USU6JRWK=
ETK-1	M1znTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvzPIdKSzVyPUG5NE4yQDFizszN	NYS4Smx1W0GQR1XS
NCI-H838	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYixcm9ZUUN3ME2xPVAvOzRizszN	MU\TRW5ITVJ?
HCE-4	NIn5V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTF7MD65PVIh\|ryP	MkP2V2FPT0WU
A2780	NHnqTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEe4b2RKSzVyPUG5Nk45QTFizszN	MkHGV2FPT0WU
COLO-668	NF74UGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjmTWM2OD1zOUOuNVU4KM7:TR?=	NHrZPXlUSU6JRWK=
HGC-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnBZZZbUUN3ME2xPVUvPTN6IN88US=>	MmTMV2FPT0WU
SW1088	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXPT2htUUN3ME2xPVUvPjd5IN88US=>	NUfjPI1xW0GQR1XS
KOSC-2	M2OzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLCTWM2OD1zOUWuPFE5KM7:TR?=	NHP5N2lUSU6JRWK=
TE-1	NFG0Wm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHUS\|djUUN3ME2xPVYvOjZizszN	NIeyTHRUSU6JRWK=
SW780	M{DyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLJV5pKSzVyPUG5Ok44OzRizszN	NEHSOXVUSU6JRWK=
22RV1	NXfmbHQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;tSmlEPTB;MUm3MlQzPCEQvF2=	NEPhTIVUSU6JRWK=
IA-LM	M3vRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HyeGlEPTB;MUm3MlgzOiEQvF2=	NV;LUGV6W0GQR1XS
TE-5	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF7OD6wN\|Mh\|ryP	NU\zbIkyW0GQR1XS
JVM-3	NFXCXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF7OD60NVkh\|ryP	NIjsdGNUSU6JRWK=
HT55	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LDbWlEPTB;MUm5MlE6OiEQvF2=	MnvkV2FPT0WU
QIMR-WIL	M3i4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCyTWM2OD1{MECuNVE3KM7:TR?=	M4rObHNCVkeHUh?=
SJRH30	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJyMD61NVUh\|ryP	NXTibG5xW0GQR1XS
COLO-679	NID0cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX0TWM2OD1{MECuPFU6KM7:TR?=	MV3TRW5ITVJ?
MDA-MB-231	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJyMD65NFIh\|ryP	MX\TRW5ITVJ?
MFM-223	NYDLfVl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFf5ZWJKSzVyPUKwNU42QDdizszN	MXfTRW5ITVJ?
MFE-280	NUXsW4xPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX62dYdqUUN3ME2yNFEvQTZzIN88US=>	M{PQeXNCVkeHUh?=
LAMA-84	M1K0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJyMj6wO\|Mh\|ryP	MkTxV2FPT0WU
LS-1034	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHL4[mVKSzVyPUKwNk42PTNizszN	MYnTRW5ITVJ?
NCI-H345	M4XFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoW3TWM2OD1{MEOuNFI4KM7:TR?=	MYDTRW5ITVJ?
KYSE-70	M4DFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLnTWM2OD1{MEOuPFc6KM7:TR?=	MV7TRW5ITVJ?
EGI-1	M1XGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEOwV5pKSzVyPUKwOE45OzNizszN	NWrGTnpxW0GQR1XS
RPMI-2650	NYHDeoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTCeZhEUUN3ME2yNFUvPDZ5IN88US=>	MWjTRW5ITVJ?
NCI-H1651	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjTb3E5UUN3ME2yNFYvPzNizszN	NFjHNW9USU6JRWK=
HPAF-II	M2HKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7PTWM2OD1{MEmuOlcyKM7:TR?=	M{XncnNCVkeHUh?=
NUGC-3	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC3[oN{UUN3ME2yNFkvPjd6IN88US=>	NFf5XYpUSU6JRWK=
DJM-1	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPZXIRKSzVyPUKwPU45QTdizszN	MXnTRW5ITVJ?
MHH-PREB-1	M1jNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P2WGlEPTB;MkGwMlM5OSEQvF2=	NGqySlJUSU6JRWK=
EW-18	M1rNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{K1bmlEPTB;MkGwMlc3OyEQvF2=	NUO4d5RRW0GQR1XS
BT-20	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjSTWM2OD1{MUCuPVg3KM7:TR?=	NHm2VYFUSU6JRWK=
A431	NFvlb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJzMT6yPVkh\|ryP	M3KwUHNCVkeHUh?=
TCCSUP	M4i0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;PfHVtUUN3ME2yNVEvPTN\|IN88US=>	M1XuN3NCVkeHUh?=
HO-1-N-1	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnGT4ltUUN3ME2yNVIvQDl2IN88US=>	MVXTRW5ITVJ?
NCI-H69	M1m2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXPTWM2OD1{MUSuNVg2KM7:TR?=	MkK1V2FPT0WU
ES7	NFLpNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fNOmlEPTB;MkG0Mlg4QCEQvF2=	M1;nRXNCVkeHUh?=
C3A	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnqTWM2OD1{MUWuOVc2KM7:TR?=	NVfwTI8xW0GQR1XS
UACC-257	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjPbYFKSzVyPUKxO{41OyEQvF2=	NWnIT\|FtW0GQR1XS
DMS-153	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2m0VGlEPTB;MkG3Mlg{PiEQvF2=	M37H[nNCVkeHUh?=
LB771-HNC	NWHqRYFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjWeIlIUUN3ME2yNVcvQDl\|IN88US=>	M{DPNnNCVkeHUh?=
HOS	NX;hcpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTRXIg6UUN3ME2yNVgvQSEQvF2=	NInmfFdUSU6JRWK=
THP-1	M1\JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTJzOT62NFYh\|ryP	M3S4OHNCVkeHUh?=
SCC-4	NEm4Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3xc5lKSzVyPUKyNE4{PTNizszN	NFe5SpFUSU6JRWK=
SCC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTS[45LUUN3ME2yNlAvPTd5IN88US=>	MoLrV2FPT0WU
BC-1	NEO0PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nYTWlEPTB;MkKwMlc6QSEQvF2=	MX3TRW5ITVJ?
NCI-H1618	NV\uR3N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTNTWM2OD1{MkGuNFE5KM7:TR?=	MmC4V2FPT0WU
CaR-1	NYLEflRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTJ{MT6yOVEh\|ryP	NEj5bHBUSU6JRWK=
NCI-H1355	NUD2RZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTJ{MT6zO\|ch\|ryP	Mmn2V2FPT0WU
NCI-H1993	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPyTWM2OD1{MkKuNlM6KM7:TR?=	M3q1VXNCVkeHUh?=
NCI-H1623	M1;YOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYWyeFg4UUN3ME2yNlIvOzh7IN88US=>	NXTnXnoxW0GQR1XS
AGS	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJ{Mj61NlMh\|ryP	MVvTRW5ITVJ?
SAS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXRTWM2OD1{MkOuO\|k3KM7:TR?=	NXHRWoZGW0GQR1XS
HCC1937	NVfVXotGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJ{ND6zPFkh\|ryP	NFrZbGVUSU6JRWK=
NCI-H209	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ{Nj61N{DPxE1?	NEfVO3lUSU6JRWK=
NCI-H322M	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzqXItKSzVyPUKyPE4xOTlizszN	NVTyXoJTW0GQR1XS
CHL-1	NVfFXJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmToTWM2OD1{MkiuNVMh\|ryP	M2qwbXNCVkeHUh?=
NCI-H630	M2P6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TERWlEPTB;MkOyMlg6PyEQvF2=	MUXTRW5ITVJ?
5637	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfUW404UUN3ME2yN\|MvODB\|IN88US=>	M3jsNnNCVkeHUh?=
MSTO-211H	NH;OeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET0OpdKSzVyPUKzN{4zPzZizszN	MV;TRW5ITVJ?
YAPC	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDyS3ZIUUN3ME2yN\|QvOjV\|IN88US=>	NFrTWHJUSU6JRWK=
SW1783	NXfy[opsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHFTWM2OD1{M{SuOFEh\|ryP	NUn0[GNpW0GQR1XS
GB-1	M3;ITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3znRWlEPTB;MkO1MlE4PyEQvF2=	MX3TRW5ITVJ?
NCI-H520	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXQTWM2OD1{M{WuO\|QyKM7:TR?=	MkLpV2FPT0WU
NOMO-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTJ\|Nj6wNkDPxE1?	MlP3V2FPT0WU
NCCIT	M3SyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTJ\|Nj64O\|Mh\|ryP	M2nYSnNCVkeHUh?=
SW954	NILS[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTlTWM2OD1{M{euPFY5KM7:TR?=	MU\TRW5ITVJ?
MOLT-4	NGXGcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEm4e4dKSzVyPUK0NU4zODlizszN	NV7rOGkzW0GQR1XS
EB2	NVvubJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fxdmlEPTB;MkSxMlkxPyEQvF2=	MYLTRW5ITVJ?
IPC-298	NVPBRWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHFN\|NKSzVyPUK0Nk4xPzJizszN	MVfTRW5ITVJ?
GP5d	M1vmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\h[GlEPTB;MkSyMlYyPiEQvF2=	NHG1Z2JUSU6JRWK=
HN	NVvufmhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jQVWlEPTB;MkSyMlk6OSEQvF2=	NFrnPFRUSU6JRWK=
BFTC-909	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJ2Mz6xNVgh\|ryP	M37XdHNCVkeHUh?=
ES5	NYrmNndOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTJ2NT6wN\|gh\|ryP	MYjTRW5ITVJ?
SK-HEP-1	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ2Nj6wOFMh\|ryP	NUeyRo1RW0GQR1XS
T47D	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jITWlEPTB;MkS3MlAyOyEQvF2=	MV;TRW5ITVJ?
KYSE-510	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLCTWM2OD1{NEeuOVE4KM7:TR?=	NGLwb2NUSU6JRWK=
LC-1F	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHSTWM2OD1{NEiuNVU3KM7:TR?=	NVPCOY43W0GQR1XS
NCI-H1693	NYjkfYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnFV\|FLUUN3ME2yOFkvPDl3IN88US=>	MWTTRW5ITVJ?
COR-L23	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjXRmgyUUN3ME2yOVAvPDF{IN88US=>	NVjX[4tWW0GQR1XS
NCI-H2228	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJ3MD64OlQh\|ryP	M{fOe3NCVkeHUh?=
NCI-H460	M2DBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfEPYxKSzVyPUK1NU41OTdizszN	M4e2VnNCVkeHUh?=
TGBC1TKB	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXhb2NsUUN3ME2yOVIvQDd3IN88US=>	MX;TRW5ITVJ?
NCI-H1304	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\SeFFwUUN3ME2yOVMvOTV4IN88US=>	MVrTRW5ITVJ?
CAL-27	NVq4dI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j3cGlEPTB;MkWzMlQ5PSEQvF2=	MYTTRW5ITVJ?
NCI-H187	NGfnXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm3XGVKSzVyPUK1Ok44PiEQvF2=	M3v0SHNCVkeHUh?=
HSC-2	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljBTWM2OD1{NUiuOVg1KM7:TR?=	NV\GWZBHW0GQR1XS
CAL-39	M3rReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWi3R3d5UUN3ME2yOlAvOjd{IN88US=>	MmTFV2FPT0WU
HuH-7	NXvPXFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TaUGlEPTB;Mk[wMlk6PiEQvF2=	MWTTRW5ITVJ?
MMAC-SF	NEW3N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGexcItKSzVyPUK2NU4yQTJizszN	Mom0V2FPT0WU
VA-ES-BJ	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrPbGxKSzVyPUK2NU46OThizszN	MX3TRW5ITVJ?
A673	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLVblVnUUN3ME2yOlcvODJ3IN88US=>	NVy0WIU6W0GQR1XS
LU-165	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjQVopKSzVyPUK2O{46PDFizszN	NYnMUnM3W0GQR1XS
CAL-12T	NWfEbG5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TGWWlEPTB;Mk[4MlM3PiEQvF2=	NI\wR5RUSU6JRWK=
RD	M3P3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHRTWM2OD1{NkmuNVE6KM7:TR?=	MWHTRW5ITVJ?
MDA-MB-468	M{f6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYW4N5Z{UUN3ME2yOlkvOzN\|IN88US=>	MV;TRW5ITVJ?
LN-405	NEi0b5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEOzS2ZKSzVyPUK2PU44ODhizszN	MUPTRW5ITVJ?
MHH-CALL-2	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rQVmlEPTB;Mk[5MlkzKM7:TR?=	NYKyOFNxW0GQR1XS
ES3	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmf2TWM2OD1{N{CuN\|U5KM7:TR?=	MkXPV2FPT0WU
SK-MEL-3	MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlqyTWM2OD1{N{WuOFU4KM7:TR?=	NGLqNGVUSU6JRWK=
TE-10	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULUV3VrUUN3ME2yO\|YvPDN7IN88US=>	NGO1XFhUSU6JRWK=
BEN	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PKZ2lEPTB;Mke2MlQ3OSEQvF2=	NX7ZdGQ2W0GQR1XS
NB69	M2C5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTJ5Nz60NFUh\|ryP	NVzJRnREW0GQR1XS
CAMA-1	NUH1WY96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHNN49pUUN3ME2yO\|gvOjd7IN88US=>	MUfTRW5ITVJ?
NCI-H1792	NG\hSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvJTWM2OD1{N{muNVg4KM7:TR?=	NELu[2dUSU6JRWK=
UACC-893	M2fBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XBOWlEPTB;MkiwMlU1KM7:TR?=	NVS2eGFOW0GQR1XS
TGW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvlTWM2OD1{OEOuNFU5KM7:TR?=	NUfCRm1SW0GQR1XS
SH-4	NXvpco5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHLNYVKSzVyPUK4N{4yOjNizszN	NIHndXNUSU6JRWK=
NCI-H2009	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\GeWlEPTB;MkizMlk2OyEQvF2=	Mn3iV2FPT0WU
T84	M2Dtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7WcolKSzVyPUK4OE43PjVizszN	NFXEXVlUSU6JRWK=
EW-7	M4DiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJ6NT6yN\|Ih\|ryP	M4ntVXNCVkeHUh?=
NCI-H1882	NGj5R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4C3WmlEPTB;Mki2MlA{PSEQvF2=	M{fENnNCVkeHUh?=
GMS-10	NXTxW\|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HSeGlEPTB;Mki3MlE5OyEQvF2=	M3HKT3NCVkeHUh?=
HC-1	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu3PWNOUUN3ME2yPVAvPjB{IN88US=>	NXH4NVlJW0GQR1XS
ABC-1	NVK3[lR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjwNZVuUUN3ME2yPVEvODZ7IN88US=>	M1PDeXNCVkeHUh?=
HuP-T3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHxOIRkUUN3ME2yPVIvOTR4IN88US=>	NWjHfoUxW0GQR1XS
HT-1197	NHToTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\hd3JKSzVyPUK5Nk45PzlizszN	MnjkV2FPT0WU
SHP-77	NVHGW2VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHuyVGdKSzVyPUK5OU42QTdizszN	M{DBUnNCVkeHUh?=
NCI-H524	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnwepVRUUN3ME2yPVUvPzZ7IN88US=>	MXLTRW5ITVJ?
SW626	NXyydGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn2fVVpUUN3ME2yPVYvOTF3IN88US=>	NFj4V25USU6JRWK=
NCI-H2347	M1my[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TNcWlEPTB;Mkm2MlQzPSEQvF2=	NXjLcJFJW0GQR1XS
U251	NH7hd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW4SlNKSzVyPUK5PE41OzhizszN	NHjreppUSU6JRWK=
RL95-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNyMD6yOFch\|ryP	NE[weXBUSU6JRWK=
C2BBe1	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TNcWlEPTB;M{CwMlY6OSEQvF2=	NYrCUnFQW0GQR1XS
HLE	NXTVNYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy1cphKSzVyPUOwNU45OThizszN	NWPqO3ZSW0GQR1XS
COLO-680N	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\4TWM2OD1\|MEKuPFk{KM7:TR?=	MVzTRW5ITVJ?
PLC-PRF-5	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PJeGlEPTB;M{C0MlkxPyEQvF2=	NHnJcmJUSU6JRWK=
SCC-15	NW\CT5ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTNyNj6wNVch\|ryP	NXzMdFVtW0GQR1XS
ECC12	NVnJdVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXtSlhKSzVyPUOxNE4zPTRizszN	MY\TRW5ITVJ?
A388	NEO5WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTrTWM2OD1\|MUKuNFIzKM7:TR?=	NY\2VY9wW0GQR1XS
ES1	NW\ZNYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTNzMj6xPFkh\|ryP	NETjWWRUSU6JRWK=
J-RT3-T3-5	NUj6bZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHvTINKSzVyPUOxN{42OjFizszN	NEnETVVUSU6JRWK=
SNU-475	M4PDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\jSYZWUUN3ME2zNVQvODlzIN88US=>	NGjuSGZUSU6JRWK=
647-V	NYjoRmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFznfWRKSzVyPUOxOE43PzNizszN	Mn\JV2FPT0WU
IMR-5	MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPD[4FxUUN3ME2zNVUvOzhizszN	NUPiWGx6W0GQR1XS
EW-24	NYTyPZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTN{MD6wO{DPxE1?	NWPINWp3W0GQR1XS
CAL-51	M{TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTN{MT60NFMh\|ryP	MYXTRW5ITVJ?
HD-MY-Z	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTN{MT60NFkh\|ryP	M2nzTXNCVkeHUh?=
EW-13	NVf5[49MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\hfWlEPTB;M{KyMlQzPCEQvF2=	MoXGV2FPT0WU
SK-N-FI	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTN{Mj60OVIh\|ryP	M4DZfHNCVkeHUh?=
BHY	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTN{Mz6xO\|Uh\|ryP	M321SXNCVkeHUh?=
OCUB-M	NXixO5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLYTWM2OD1\|MkOuOFM1KM7:TR?=	NFLSSIhUSU6JRWK=
HCC1954	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTN{Mz61PFIh\|ryP	M1LtV3NCVkeHUh?=
SK-MEL-24	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTN{ND6xNVEh\|ryP	M2HXVnNCVkeHUh?=
NTERA-S-cl-D1	NFTTdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLuTWM2OD1\|Mk[uOFg6KM7:TR?=	NGC1SVRUSU6JRWK=
SK-MEL-30	NY[zWnF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHu0TFBKSzVyPUOyOk44OzhizszN	Mlz1V2FPT0WU
LS-123	NXrC[YFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjYZZJQUUN3ME2zNlgvOTZ2IN88US=>	MW\TRW5ITVJ?
SF268	NYPabXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX63dphQUUN3ME2zN\|AvOjZ3IN88US=>	MlnvV2FPT0WU
BT-474	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrPc\|JKSzVyPUOzNk41OThizszN	MlzMV2FPT0WU
NCI-H1522	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rvUWlEPTB;M{O0MlM{QSEQvF2=	NWXhOWYxW0GQR1XS
LC-2-ad	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLwTWM2OD1\|M{[uOVkyKM7:TR?=	MVnTRW5ITVJ?
LAN-6	NHvVdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XKUGlEPTB;M{O2Mlk4PyEQvF2=	MkHuV2FPT0WU
ARH-77	NEW5To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN\|Nz6zNkDPxE1?	NWr3[3A{W0GQR1XS
HuO9	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrsXmVOUUN3ME2zN\|cvPDdizszN	NFPTXWlUSU6JRWK=
MLMA	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDUe3JKSzVyPUOzPE4yPTVizszN	M{Lj[HNCVkeHUh?=
Raji	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTN\|OD6zPEDPxE1?	MkXZV2FPT0WU
GT3TKB	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPONXh2UUN3ME2zN\|gvPDF{IN88US=>	MlvuV2FPT0WU
NCI-H441	NIfzNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXvTWM2OD1\|NEGuOFE5KM7:TR?=	MWHTRW5ITVJ?
NCI-H2030	NXjPS29IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnKxTWM2OD1\|NEGuOlA6KM7:TR?=	MYnTRW5ITVJ?
VM-CUB-1	M4DsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDCW\|lKSzVyPUO0Nk43OzZizszN	M1XvS3NCVkeHUh?=
KP-4	NELyZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu4d4tTUUN3ME2zOFMvPzN\|IN88US=>	NGjlVWpUSU6JRWK=
PF-382	M3HI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTN2ND60NlIh\|ryP	NVO3Oo95W0GQR1XS
NB13	NV;sRXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvQRW9KSzVyPUO0OU42QCEQvF2=	NGTTR29USU6JRWK=
D-502MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TqTGlEPTB;M{S1MlgyOiEQvF2=	NEL5XopUSU6JRWK=
CAL-54	NF;WOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrheWRKSzVyPUO0OU45PzlizszN	NHHpUYlUSU6JRWK=
DOHH-2	M3SzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrjTWM2OD1\|NE[uOlUh\|ryP	MlnsV2FPT0WU
SK-PN-DW	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnQXZNKSzVyPUO0O{41OjZizszN	NE[3d49USU6JRWK=
NCI-H720	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7sW4JNUUN3ME2zOFkvQDR4IN88US=>	NUe3flFkW0GQR1XS
SW1990	M4jrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzleFFKSzVyPUO1NU4zQCEQvF2=	MV3TRW5ITVJ?
NCI-H2196	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG5TWM2OD1\|NUKuOlI1KM7:TR?=	MWnTRW5ITVJ?
P30-OHK	NWT4UVJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jwemlEPTB;M{WzMlA3OyEQvF2=	MUHTRW5ITVJ?
NCI-H358	NG\lSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;3cW02UUN3ME2zOVUvOzV4IN88US=>	MXfTRW5ITVJ?
CW-2	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nNdmlEPTB;M{W2MlUzQSEQvF2=	NHSwSJpUSU6JRWK=
COLO-678	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zj[GlEPTB;M{W3Mlg3OyEQvF2=	MWPTRW5ITVJ?
NCI-H2126	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoriTWM2OD1\|NUiuOVIyKM7:TR?=	Mk\KV2FPT0WU
DMS-53	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLpTWM2OD1\|NUiuO\|EyKM7:TR?=	MoDUV2FPT0WU
NCI-H1838	M1;YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4P1[mlEPTB;M{W5Mlk5PyEQvF2=	NV3mTlFZW0GQR1XS
SJSA-1	M1T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPPcnRKSzVyPUO2NE46OzlizszN	MUTTRW5ITVJ?
ChaGo-K-1	NGixXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TtTmlEPTB;M{[zMlkzPCEQvF2=	MlHrV2FPT0WU
IST-SL2	NIHZeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTN5Mj65NlYh\|ryP	M2XMNXNCVkeHUh?=
U-266	NEP3XIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn30TWM2OD1\|N{OuNVMzKM7:TR?=	MYfTRW5ITVJ?
P31-FUJ	M{jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN5Nj65OlQh\|ryP	NF;NOm5USU6JRWK=
HCC2157	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vKUGlEPTB;M{e4MlE3OSEQvF2=	NXfSVpdZW0GQR1XS
COR-L88	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvXXoZKSzVyPUO4N{43PzdizszN	NIqxfo5USU6JRWK=
NCI-H596	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;vNmlEPTB;M{i1MlM1KM7:TR?=	M1P2PXNCVkeHUh?=
GOTO	NHPNVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\xTVJKSzVyPUO5NE43PDFizszN	M{DwdXNCVkeHUh?=
NCI-H719	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;BTWM2OD1\|OUGuPFk{KM7:TR?=	MmLBV2FPT0WU
MN-60	NF7FSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\ZbmdKSzVyPUO5N{46PDhizszN	NUe5b4JtW0GQR1XS
IST-SL1	NITPflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnKTWM2OD1\|OUSuOFA3KM7:TR?=	MV;TRW5ITVJ?
TE-6	NIntPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rtXmlEPTB;M{m3MlI2PCEQvF2=	MULTRW5ITVJ?
SW962	M3nTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;lTWM2OD1\|OUiuOlkh\|ryP	M3PWS3NCVkeHUh?=
FADU	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T2e2lEPTB;NECzMlA5OyEQvF2=	MXrTRW5ITVJ?
ECC4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\n[2lEPTB;NEC4MlQ2QCEQvF2=	M37rXHNCVkeHUh?=
MES-SA	NWHLVG1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq1TI1XUUN3ME20NFkvQThizszN	MVvTRW5ITVJ?
NCI-H716	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRzMD6wO\|Uh\|ryP	MYXTRW5ITVJ?
GR-ST	M4nmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHWXWNKSzVyPUSxNE41QTdizszN	NIn1SlZUSU6JRWK=
KY821	NFPtOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTRzND6wPFYh\|ryP	Mk\SV2FPT0WU
NCI-H2141	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\rNng3UUN3ME20NlQvOzh6IN88US=>	MYDTRW5ITVJ?
MDA-MB-134-VI	NGTUdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7EeW9UUUN3ME20N\|EvODN\|IN88US=>	MkTkV2FPT0WU
RH-1	M17afGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHflOGtKSzVyPUSzOU4xQSEQvF2=	MoTaV2FPT0WU
AM-38	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jxcmlEPTB;NEO4MlU1KM7:TR?=	MVHTRW5ITVJ?
BL-70	NGf0[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTR\|OT60Nlkh\|ryP	M4HHPHNCVkeHUh?=
COLO-684	NHfqRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInpcYxKSzVyPUS0PE45QDhizszN	M4PwcXNCVkeHUh?=
DMS-79	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\TTWM2OD12NEmuOlgh\|ryP	NFm3bGNUSU6JRWK=
EW-1	M4jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXxTWM2OD12NUKuPFg5KM7:TR?=	NYLNOGx5W0GQR1XS
MS-1	NV;oZm5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnkT4JKSzVyPUS1OE4{QDVizszN	MnHqV2FPT0WU
A4-Fuk	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTR3ND61NFch\|ryP	MWXTRW5ITVJ?
TALL-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmGwTWM2OD12NUWuNlk4KM7:TR?=	NYK3SY54W0GQR1XS
SCLC-21H	M4\L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\BfHFKSzVyPUS1OU43QTlizszN	MkfFV2FPT0WU
KMS-12-PE	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjuN3ZKSzVyPUS1Ok45OjJizszN	M3X3PHNCVkeHUh?=
TE-441-T	M13MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWCydFhiUUN3ME20OVcvOTh4IN88US=>	NHu1SWxUSU6JRWK=
A3-KAW	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkmxTWM2OD12NkCuPFQyKM7:TR?=	NUW0ZXRwW0GQR1XS
NCI-H1092	M2\kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTR4Mz65OFMh\|ryP	NWfvWIVIW0GQR1XS
COR-L279	NWKwbnM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTR4ND64OFch\|ryP	M3roSHNCVkeHUh?=
NCI-SNU-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHqWGlKSzVyPUS3Nk4zQCEQvF2=	MYjTRW5ITVJ?
JAR	NYfWfGRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK3SWxjUUN3ME20O\|QvPzh6IN88US=>	MVfTRW5ITVJ?
NCI-H446	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzzbWF2UUN3ME20O\|cvODhizszN	MVjTRW5ITVJ?
HDLM-2	M{D1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUX1[nRyUUN3ME20PFAvQDZ7IN88US=>	M4LYUnNCVkeHUh?=
D-283MED	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\ySZNHUUN3ME20PFgvQTJ2IN88US=>	MVnTRW5ITVJ?
NCI-H1395	M{L1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonBTWM2OD12OEmuNFA1KM7:TR?=	MWjTRW5ITVJ?
RPMI-6666	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\4N\|JxUUN3ME20PVEvOzl6IN88US=>	MYPTRW5ITVJ?
CPC-N	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fLcGlEPTB;NUCyMlA3OyEQvF2=	NX;Xc212W0GQR1XS
EC-GI-10	M4O3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mor3TWM2OD13MEKuNVY6KM7:TR?=	Mne3V2FPT0WU
CA46	NGr1[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fRdmlEPTB;NUC0MlQxPyEQvF2=	NXTN[o9kW0GQR1XS
EHEB	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFu0OFVKSzVyPUWwO{4zODhizszN	NVPVR45pW0GQR1XS
RPMI-8402	MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL1bYJ6UUN3ME21NVAvODJzIN88US=>	MlG2V2FPT0WU
DU-4475	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXOxUItCUUN3ME21NVEvOTBzIN88US=>	MUPTRW5ITVJ?
P12-ICHIKAWA	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXx[\|hbUUN3ME21NVEvPDF4IN88US=>	Mk\rV2FPT0WU
NCI-H1694	NGn4d5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jIOGlEPTB;NUGyMlQ{QSEQvF2=	M3Xjb3NCVkeHUh?=
NCI-H2171	NIrXUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTVzMj63NFUh\|ryP	M3jOPXNCVkeHUh?=
Mo-T	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTVzNT6xNVYh\|ryP	NFPrVJZUSU6JRWK=
HL-60	MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTV{Mj65NlQh\|ryP	MmLBV2FPT0WU
NCI-H1436	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7Wc4lwUUN3ME21NlMvODZ2IN88US=>	MVLTRW5ITVJ?
NCI-H510A	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjrWG5KSzVyPUWyOE43QTZizszN	MWTTRW5ITVJ?
NCI-H2081	NXy0bYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTV{NT61NVMh\|ryP	MYHTRW5ITVJ?
NB5	M1zTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPFUYpKSzVyPUWyOk41OyEQvF2=	NF\tRZBUSU6JRWK=
NCI-H2227	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHW0R\|FKSzVyPUWzNE4zPTRizszN	NYKyUWp3W0GQR1XS
HSC-4	NVu4OIR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXRTWM2OD13M{muNlk{KM7:TR?=	MXXTRW5ITVJ?
RL	NXTVd4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPQTWM2OD13NEKuOFQzKM7:TR?=	MXTTRW5ITVJ?
EVSA-T	NIm2TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTV2Mz62PFQh\|ryP	M33OdnNCVkeHUh?=
NCI-H889	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DOT2lEPTB;NUS3MlI{KM7:TR?=	MmjBV2FPT0WU
COLO-320-HSR	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HVRWlEPTB;NUWxMlM2KM7:TR?=	NFfDcYhUSU6JRWK=
EW-11	NV7JSlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTV3Mj6zPVkh\|ryP	MmK0V2FPT0WU
UACC-812	NVy5RmtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHZVnNKSzVyPUW1PU4{QTFizszN	M4nNUHNCVkeHUh?=
CAL-148	NWfWU5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTV4NT6wPFkh\|ryP	M3fmRXNCVkeHUh?=
K052	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXsbG01UUN3ME21O\|kvOjF\|IN88US=>	MnuxV2FPT0WU
L-428	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DFe2lEPTB;NkCwMlY4OSEQvF2=	NV3OT\|I{W0GQR1XS
LP-1	M1rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\SXGlEPTB;NkCzMlU5PyEQvF2=	M1PSOnNCVkeHUh?=
ML-2	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTj[JJKSzVyPU[wOk42PzlizszN	MYnTRW5ITVJ?
KARPAS-45	M3;keGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml[3TWM2OD14MUiuNlIyKM7:TR?=	MorrV2FPT0WU
HT	NGTacHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvuTWM2OD14MkKuO\|g2KM7:TR?=	MlG5V2FPT0WU
NCI-H226	NYPXOmhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jxWWlEPTB;NkK4MlM2OyEQvF2=	MWPTRW5ITVJ?
L-363	NFLQfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrDR4RKSzVyPU[0PE4xPjRizszN	NYjz[4NrW0GQR1XS
IM-9	M3W1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFf2dmpKSzVyPU[1NU42PDFizszN	MYrTRW5ITVJ?
TUR	NWHN[W9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXZTGRKSzVyPU[3NU4{OjJizszN	M4D5SHNCVkeHUh?=
NCI-SNU-16	M2LHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTmZpdVUUN3ME22PFAvPDZ{IN88US=>	MV\TRW5ITVJ?
NCI-SNU-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEeybYlKSzVyPU[5NE4yPzJizszN	Mn\OV2FPT0WU
U-87-MG	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPUNlhKSzVyPU[5OE42QDVizszN	M3vv[XNCVkeHUh?=
KM-H2	NIHSbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTZ7OT6wOVkh\|ryP	MWTTRW5ITVJ?
DEL	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvudHc2UUN3ME23NFAvQDN6IN88US=>	MnL0V2FPT0WU
KARPAS-422	M3LQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fQfWlEPTB;N{i5MlMyPSEQvF2=	MXXTRW5ITVJ?
BC-3	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG5TWM2OD16MEWuNlA{KM7:TR?=	NGPKSo9USU6JRWK=
NCI-H1155	M1nW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X4OmlEPTB;OEG4MlA2QSEQvF2=	M1zLVXNCVkeHUh?=
NCI-H1581	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrFTWM2OD17MECuNlMyKM7:TR?=	MWTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / CD31 / VE-Cadherin / α-SMA / vimentin; PubMed: 30709379 J Exp Clin Cancer Res NCI-H460 cells were co-cultured with HUVECs in a 3D culture system, and then treated with 1 μM CHIR-99021, 10 μM or 20 μM Cisplatin, or a combination of both, for 24 h. Cells were harvested and immunoblotted with anti-cleaved PARP, anti-CD31, anti-VE-cadherin, anti-α-SMA, anti-vimentin, and anti-β-actin antibodies. CTNNB1; PubMed: 23993102 Cell Treatment with the GSK3β inhibitor CHIR-99021 led to increased levels of β-catenin in RKO and HT29 (non-mutant) cells. β-catenin; PubMed: 24165128 J Biol Chem HeLa cells were treated with 5 μm CHIR-99021 for the indicated times. The samples were analyzed by Western blot.	30709379 23993102 24165128
Growth inhibition assay	Cell viability; PubMed: 22039301 J Immunol HMC-1.2 cells were cultured in the absence or presence of GSK3β inhibitor (CHIR 99021, 3–30 µM) and viability cell count was assessed by trypan blue dye exclusion after 24 h, 48 h or 72 h. All data are presented as the mean ± SEM of three independent experiments conducted in triplicate. p < 0.05, p < 0.001* p < 0.0001*** vs vehicle treated control cells.	22039301
Immunofluorescence	SOX10 / EdU; PubMed: 28174705 Cell Mol Gastroenterol Hepatol Incorporation of EdU (white arrowheads) into SOX10+ ENS (enteric nervous system) cells with and without CHIR-99021. Oct3/4; PubMed: 24779365 BMC Res Notes Fluorescence micrographs showing the protein expression of Brachyury/Oct3/4 after a three day differentiation of ES-D3 cells with BIO (0.5 μM), SB-216763 (5 μM), CHIR-99021 (5 μM), or CHIR-98014 (1 μM). Nuclei were counterstained with DAPI (blue). The merge is shown in yellow. Original magnification 400x. Scale bar = 50 μm.	28174705 24779365

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	- Collapse Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Formulation: Formulated as solutions in 20 mM citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose. Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Ethanol	2 mg/mL (3.98 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 126 Publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl

Cited by 126 Publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Related GSK-3 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)